Literature DB >> 16953421

[The serotonin syndrome. Fatal course of intoxication with citalopram and moclobemide].

S Cassens1, E A Nickel, M Quintel, P Neumann.   

Abstract

The serotonin syndrome is caused by a drug-induced increase of the intrasynaptic serotonin concentration. Milder forms of the syndrome may be difficult to diagnose because of the variability of symptoms. Severe forms often rapidly turn into a life-threatening situation, therefore the serotonin syndrome may be a challenge for physicians. We describe the pathophysiology and therapeutic options of the serotonin syndrome and report about a 42-year-old female patient who ingested large amounts of moclobemide, a monoamine oxidase inhibitor, and citalopram, a selective serotonin reuptake inhibitor, for attempted suicide. Within a few hours the patient developed a lethal serotonin syndrome although ICU therapy was initiated immediately.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16953421     DOI: 10.1007/s00101-006-1089-1

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  21 in total

1.  Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome.

Authors:  K Nisijima; T Yoshino; K Yui; S Katoh
Journal:  Brain Res       Date:  2001-01-26       Impact factor: 3.252

Review 2.  The serotonin syndrome and its treatment.

Authors:  P K Gillman
Journal:  J Psychopharmacol       Date:  1999       Impact factor: 4.153

3.  Nitroglycerin in the treatment of the serotonin syndrome.

Authors:  Thomas M Brown
Journal:  Am J Emerg Med       Date:  2004-10       Impact factor: 2.469

Review 4.  The serotonin syndrome.

Authors:  D Bijl
Journal:  Neth J Med       Date:  2004-10       Impact factor: 1.422

5.  The serotonin syndrome.

Authors:  Peter K Gillman
Journal:  N Engl J Med       Date:  2005-06-09       Impact factor: 91.245

Review 6.  A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action.

Authors:  P Ken Gillman
Journal:  Biol Psychiatry       Date:  2006-02-07       Impact factor: 13.382

7.  Risperidone counteracts lethality in an animal model of the serotonin syndrome.

Authors:  K Nisijima; T Yoshino; T Ishiguro
Journal:  Psychopharmacology (Berl)       Date:  2000-05       Impact factor: 4.530

8.  The serotonin syndrome scale: first results on validity.

Authors:  U Hegerl; R Bottlender; J Gallinat; H J Kuss; M Ackenheil; H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1998       Impact factor: 5.270

Review 9.  Serotonin syndrome and other serotonergic disorders.

Authors:  Rasih Atilla Ener; Sharon B Meglathery; William A Van Decker; Rollin M Gallagher
Journal:  Pain Med       Date:  2003-03       Impact factor: 3.750

10.  Functional study of rat 5-HT2A receptors using antisense oligonucleotides.

Authors:  Dirk Van Oekelen; Anton Megens; Theo Meert; Walter H M L Luyten; Josée E Leysen
Journal:  J Neurochem       Date:  2003-06       Impact factor: 5.372

View more
  3 in total

Review 1.  [Herbal medications. Possible importance for anaesthesia and intensive care medicine].

Authors:  S Kleinschmidt; G Rump; J Kotter
Journal:  Anaesthesist       Date:  2007-12       Impact factor: 1.041

Review 2.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

3.  Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.

Authors:  R R Ramsay; C Dunford; P K Gillman
Journal:  Br J Pharmacol       Date:  2007-08-27       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.